JP2022533432A5 - - Google Patents

Info

Publication number
JP2022533432A5
JP2022533432A5 JP2021569353A JP2021569353A JP2022533432A5 JP 2022533432 A5 JP2022533432 A5 JP 2022533432A5 JP 2021569353 A JP2021569353 A JP 2021569353A JP 2021569353 A JP2021569353 A JP 2021569353A JP 2022533432 A5 JP2022533432 A5 JP 2022533432A5
Authority
JP
Japan
Prior art keywords
seq
sequence
tdp
amino acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064335 external-priority patent/WO2020234473A1/en
Publication of JP2022533432A publication Critical patent/JP2022533432A/ja
Publication of JP2022533432A5 publication Critical patent/JP2022533432A5/ja
Priority to JP2025050500A priority Critical patent/JP2025094219A/ja
Pending legal-status Critical Current

Links

JP2021569353A 2019-05-23 2020-05-22 抗tdp-43結合分子およびその使用 Pending JP2022533432A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050500A JP2025094219A (ja) 2019-05-23 2025-03-25 抗tdp-43結合分子およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19176314 2019-05-23
EP19176314.3 2019-05-23
EP19195916 2019-09-06
EP19195916.2 2019-09-06
EP19207839 2019-11-07
EP19207839.2 2019-11-07
EP20161060.7 2020-03-04
EP20161060 2020-03-04
PCT/EP2020/064335 WO2020234473A1 (en) 2019-05-23 2020-05-22 Anti-tdp-43 binding molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050500A Division JP2025094219A (ja) 2019-05-23 2025-03-25 抗tdp-43結合分子およびその使用

Publications (2)

Publication Number Publication Date
JP2022533432A JP2022533432A (ja) 2022-07-22
JP2022533432A5 true JP2022533432A5 (cg-RX-API-DMAC7.html) 2023-05-24

Family

ID=70779783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569353A Pending JP2022533432A (ja) 2019-05-23 2020-05-22 抗tdp-43結合分子およびその使用
JP2025050500A Pending JP2025094219A (ja) 2019-05-23 2025-03-25 抗tdp-43結合分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050500A Pending JP2025094219A (ja) 2019-05-23 2025-03-25 抗tdp-43結合分子およびその使用

Country Status (14)

Country Link
US (1) US12600766B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972692A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022533432A (cg-RX-API-DMAC7.html)
KR (1) KR20220012270A (cg-RX-API-DMAC7.html)
CN (2) CN114008073B (cg-RX-API-DMAC7.html)
BR (1) BR112021023487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137882A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003027A1 (cg-RX-API-DMAC7.html)
IL (1) IL288314A (cg-RX-API-DMAC7.html)
MX (1) MX2021014274A (cg-RX-API-DMAC7.html)
PH (1) PH12021552938A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112453TA (cg-RX-API-DMAC7.html)
TW (1) TW202110879A (cg-RX-API-DMAC7.html)
WO (1) WO2020234473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
WO2022174036A2 (en) * 2021-02-11 2022-08-18 Mayo Foundation For Medical Education And Research Methods and materials for treating tdp-43 proteinopathies
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
IL316153A (en) 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
EP4389215A1 (en) * 2022-12-20 2024-06-26 Consejo Superior De Investigaciones Científicas Chemically modified tdp-43 derived polypeptides and uses thereof
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
KR102859015B1 (ko) * 2023-07-20 2025-09-12 충북대학교 산학협력단 c­Abl에 의한 TDP­43의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
CN117126269B (zh) * 2023-10-25 2024-02-13 首都儿科研究所 一种1型人博卡病毒型别特异性抗体及其应用
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026132413A1 (en) 2024-12-20 2026-06-25 Bioarctic Ab Antibody against tdp-43
EP4781999A1 (en) * 2025-01-24 2026-07-29 Brainever Engrailed protein for use in the treatment of tdp-43 proteinopathies

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5688511A (en) 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008151055A1 (en) * 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2853412C (en) * 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
EP2825197B1 (en) 2012-03-16 2018-06-06 Covagen AG Novel binding molecules with antitumoral activity
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
JP7761373B2 (ja) 2017-05-30 2025-10-28 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア Tdp-43のrna認識モチーフ1(rrm1)中のエピトープ、およびそれらに対するミスフォールディング選択的抗体

Similar Documents

Publication Publication Date Title
JP7626416B2 (ja) 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
CN114008073B (zh) 抗tdp-43结合分子及其用途
US9512224B2 (en) Use of semaphorin-4D binding molecules for treatment of atherosclerosis
JP2025507569A5 (cg-RX-API-DMAC7.html)
JP6955721B2 (ja) RGMa結合タンパク質及びその使用
JP2023537761A5 (cg-RX-API-DMAC7.html)
JP7246320B2 (ja) ヒト抗セマフォリン4d抗体
JP7499228B2 (ja) 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用
KR102105436B1 (ko) 뇌졸중 후 신경발생을 촉진시키는 세마포린-4d 결합 분자의 용도
EP3854875B1 (en) Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody
JP2022033757A (ja) タウオパチーを治療するための組成物及び方法
AU2017434556A1 (en) Dosing regimes for treatment of synucleinopathies
JP2025513799A5 (cg-RX-API-DMAC7.html)
JP2022547993A5 (cg-RX-API-DMAC7.html)
JP2024544997A5 (cg-RX-API-DMAC7.html)
JP7610767B2 (ja) レット症候群の処置のためのセマフォリン4d結合分子の使用
TW201840583A (zh) 對β-類澱粉肽的初原纖維形式具有特異性的抗體之神經細胞保護作用
JP2023552919A5 (cg-RX-API-DMAC7.html)
EP4537842A1 (en) Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging
JP2024535403A (ja) 神経変性障害を処置するための抗セマフォリン4d結合分子の使用に関する予測アウトカムプロファイリング
RU2575629C2 (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
AU2024342582A1 (en) Anti-tdp-43 antibodies and uses thereof
WO2025037271A1 (en) Plasma assay for detecting cns-derived tau peptides
EP4522655A1 (en) In utero treatment of a fetus having genetic disease/neuromuscular disease